Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07454135

Mechanisms of Atrial Pathoelectrophysiology in HCM

This study aims to learn why atrial fibrillation (AF), a type of irregular heartbeat, happens more often and is harder to treat in people with hypertrophic cardiomyopathy (HCM). HCM is an inherited condition where the heart muscle is thicker than usual.

Researchers will study electrical signals from the heart and advanced heart imaging. By doing this, they hope to better understand how AF behaves in people with HCM and why treatments may not work as well for them.

The information from this study may help improve future treatments for people who have both HCM and AF.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Hypertrophic Cardiomyopathy (HCM) Aortic Stenosis, Subvalvular Aortic Valve Disease Aortic Valve Stenosis Arrhythmias, Cardiac Atrial Fibrillation Atrial Fibrillation (AF) Cardiomyopathies Cardiomyopathy, Hypertrophic Cardiovascular Diseases Heart Diseases Heart Valve Diseases Pathologic Processes Pathological Conditions, Signs and Symptoms

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Paroxysmal or persistent atrial fibrillation
  • Diagnosis of hypertrophic cardiomyopathy
  • Patient planning to proceed to atrial fibrillation ablation following clinical consultation
  • Age 18-80 years
  • Able and willing to provide written informed consent
  • Able and willing to comply with study follow up requirements

Exclusion criteria

  • Any clinical contra-indication to ablation
  • Any disease limiting life expectancy to <1 year
  • Potential participant currently pregnant or breast feeding
  • Contraindication to MRI including renal dysfunction (eGFR<30ml/min)
  • Unable to understand verbal or written explanations given in English

Treatment and study plan

Primary outcomes

  1. Changes in bipolar voltage, conduction velocity, refractory periods and conduction divergence of the atria in patients with HCM and AF compared to patients with AF and structurally normal hearts

    Time frame: At the time of the clinical ablation procedure

Secondary outcomes

  1. Correlatation between the bipolar voltage in the atria with directly measured left atrial pressure, extent of late gadolinium enhancement and ventricular extracellular volume .

    Time frame: At the time of clinical ablation procedure

  2. Reduction in AF inducibility in silico models following simulated ablation

    Time frame: Based on measurements taken during the clinical ablation procedure

Sponsors and collaborators

Lead sponsor

Guy's and St Thomas' NHS Foundation Trust

Other

Collaborators

  • King's College London

Registry information

Acronym: MAP HCM

Important dates

Study start
2026
Primary completion
2027
Study completion
2027
First posted
Mar 6, 2026
Registry last updated
Apr 6, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.